ClinicalTrials.Veeva

Menu

Retinal Neuro-vascular Coupling in Patients With Non-arteritic Anterior Ischemic Optic Neuropathy

Medical University of Vienna logo

Medical University of Vienna

Status

Completed

Conditions

Anterior Ischemic Optic Neuropathy

Treatments

Device: Optical coherence tomography (OCT)
Device: Fourier Domain Doppler Optical Coherence Tomography (FDOCT)
Device: Dynamic Vessel Analyzer (DVA)

Study type

Interventional

Funder types

Other

Identifiers

NCT03401892
OPHT-210917

Details and patient eligibility

About

Ischemic optic neuropathy is among the most common causes of serious impaired vision in the middle-aged and elderly population in the western world. The current study focuses on a subgroup of ischemic optic neuropathy, the so-called non-arteritic ischemic optic neuropathy (NAION). Although the exact pathogenesis of NAION has not been fully clarified it is known that patients with cardio-vascular risk factors such as hypertension, diabetes mellitus and dyslipidemia have also an increased risk to develop NAION. Along this line of thought it has been shown that patients with a history of NAION in one eye have an increased risk to develop NAION also on the contralateral eye. However, clinical studies investigating ocular perfusion abnormalities in patients with NAION are sparse and even contradicting. Thus, the current study seeks to measure ocular blood flow parameters in patients with a history of NAION and compare it to healthy age-matched subjects.

Enrollment

1 patient

Sex

All

Ages

18+ years old

Volunteers

Accepts Healthy Volunteers

Inclusion and exclusion criteria

Inclusion criteria for healthy subjects:

  • Men and women aged over 18 years
  • Non-smokers
  • Normal findings in the medical history unless the investigator considers an abnormality to be clinically irrelevant
  • Normal ophthalmic findings, ametropy < 6 Dpt.

Inclusion criteria for patients with NAION:

  • Men and women aged over 18 years
  • History of NAION in one eye
  • Normal ophthalmic findings, ametropy < 6 Dpt.
  • Adequate visual acuity to allow participation in the ocular blood flow measurements
  • A potential participant has to be on stable doses of all medications he/she is taking because of consisting illnesses according to medical history for at least 30 days prior inclusion, if considered relevant by the investigator.

Any of the following will exclude a healthy subject from the study:

  • Current ocular disease or history of NAION
  • Presence or history of a severe medical condition as judged by the clinical investigator
  • Untreated Arterial hypertension
  • History or family history of epilepsy
  • Presence of any abnormalities preventing reliable measurements in the study eye as judged by the investigator
  • Best corrected visual acuity < 0.5 Snellen
  • Ametropy ≥ 6 Dpt
  • Pregnancy or planned pregnancy
  • Alcoholism or substance abuse

Any of the following will exclude a patient from the study:

  • Presence or history of a severe medical condition other NAION as judged by the clinical investigator
  • Untreated Arterial hypertension
  • History or family history of epilepsy
  • Presence of any abnormalities preventing reliable measurements in the study eye as judged by the investigator
  • Best corrected visual acuity < 0.5 Snellen in the non-affected eye
  • Ametropy ≥ 6 Dpt
  • Pregnancy, planned pregnancy
  • Alcoholism or substance abuse

Trial design

Primary purpose

Basic Science

Allocation

Non-Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

1 participants in 2 patient groups

Patients with a history of NAION
Experimental group
Description:
patients with a history of non-arteritic anterior ischemic optic neuropathy (NAION) in one eye
Treatment:
Device: Optical coherence tomography (OCT)
Device: Dynamic Vessel Analyzer (DVA)
Device: Fourier Domain Doppler Optical Coherence Tomography (FDOCT)
Healthy control subjects
Experimental group
Description:
healthy age-and sex- matched control subjects
Treatment:
Device: Optical coherence tomography (OCT)
Device: Dynamic Vessel Analyzer (DVA)
Device: Fourier Domain Doppler Optical Coherence Tomography (FDOCT)

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems